Connor, Clark & Lunn Investment Management Ltd. Alector, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$6.88 - $9.55 $1.51 Million - $2.1 Million	-219,722 Reduced 66.26%	111,888 $1.03 Million
Q3 2022 Nov 10, 2022	BUY	$8.19 - $13.2 $1.22 Million - $1.97 Million	148,924 Added 81.52%	331,610 $3.14 Million
Q2 2022 Aug 05, 2022	BUY	$7.65 - $14.24 $658,481 - $1.23 Million	86,076 Added 89.1%	182,686 $1.86 Million
Q1 2022 May 12, 2022	BUY	$13.02 - $20.78 $175,509 - $280,114	13,480 Added 16.22%	96,610 $1.38 Million
Q4 2021 Feb 10, 2022	BUY	$19.35 - $25.54 $1.09 Million - $1.44 Million	56,454 Added 211.63%	83,130 $1.72 Million
Q3 2021 Nov 12, 2021	BUY	$21.65 - $39.49 $577,535 - $1.05 Million	26,676 New	26,676 $609,000

Others Institutions Holding ALEC

# of Institutions

155

Shares Held

55M

Call Options Held

39.7K

Put Options Held

51K

Ra Capital Management, L.P. Boston, MA

9.7M
Shares

$18.1 Million
0.3% of portfolio
Black Rock Inc. New York, NY

9.1M
Shares

$17 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.62M
Shares

$10.5 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.91M
Shares

$3.58 Million
0.0% of portfolio
State Street Corp Boston, MA

1.85M
Shares

$3.46 Million
0.0% of portfolio

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $154M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account